

**Myeloma “The State of the Art”: An interactive course**  
 11–12 May 2017  
 Mayo Clinic, Rochester, Minnesota, USA

**Agenda: Day One (May 11, 2017)**

Agenda: Time	Session title	Speaker
08:30	Introduction and Welcome	Shaji Kumar ,MD Prashant Kapoor, MD
08:35	Monoclonal gammopathies: Diagnostic considerations	Vincent Rajkumar, MD
9:05	Epidemiology of myeloma and precursor conditions	Robert A. Kyle, MD
9:35	Initial work up of myeloma: Pathological considerations	Dragan Jevremovic, MD, PhD
10:05	Break	
10:15	Assessment of Myeloma Bone Disease	Mathew Drake, MD, PhD
10:40	Cytogenetics and FISH studies	Rhett Ketterling, MD
11:10	Multiple myeloma: Risk stratification	Prashant Kapoor, MD
11:50	Smoldering myeloma: Current Approaches	John Lust, MD, PhD
12:30–13:30	Lunch	
13:30	Initial therapy of myeloma: transplant-eligible patients	Shaji Kumar, MD
14:30	Role of Stem Cell Transplantation in Myeloma	Morie A. Gertz, MD
15:30	Supportive Care in Multiple Myeloma	Ronald Go, MD
16:00	Break	
16:15	Monoclonal protein studies including FLC assays	David Murray, MD, PhD
16:45	Monoclonal Gammopathies and the kidney	Nelson Leung, MD
18:00	Evening social function, Tour of Mayo Clinic followed by dinner	

**Agenda: Day Two (May 12, 2017)**

Time	Session title	
08:00	Post-Transplant Approaches in Myeloma	Francis Buadi, MD
08:45	Initial Therapy of Myeloma: Transplant Ineligible patients	Martha Q. Lacy, MD
9:30	Diagnostic considerations in relapsed myeloma	David Dingli, MD, PhD
10:00	Break	
10:15	Treatment approaches for relapsed myeloma	David Dingli, MD, PhD
11:00	Light chain amyloidosis: Diagnosis and treatment	Angela Dispenzieri, MD
12:00–13:00	Lunch	
13:00	Counseling myeloma patients regarding therapy: tips from a pharmacist	Kristen MuCullough, Pharm.D., R.Ph.
13:30	Proteasome inhibitors and Immunomodulatory Drugs: Current status	Wilson Gonsalves, MD
14:10	Monoclonal Antibodies and CAR T-cell therapy in Myeloma: Current status	Yi Lin, MD, PhD ( <b>Decline</b> )
14:40	Emerging novel drugs in myeloma	Taxiarchis Kourelis, MD
15:10	Break	
15:25	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma	Shaji Kumar, MD
16:00	Uncommon plasma cell disorders	Rahma Warsame, MD
16:30	Plasma Cell Leukemia	Wilson Gonsalves, MD
16:55	Waldenstrom Macroglobulinemia	Prashant Kapoor, MD
17:45	Concluding Remarks	